Related Experiment Videos
[Class III beta tubulin expression in nonsmall cell lung cancer]
1Inserm U. 590, pharmacogénomique et chimiorésistance, laboratoire de cytologie analytique, faculté de médecine Rockefeller, 8, avenue Rockfeller, 69373, Lyon cedex 08, France. pascal.seve@chu-lyon.fr
Introduction:
Several investigators have addressed the relationship between expression of class III beta-tubulin and outcome in patients with nonsmall cell lung cancer (NSCLC) treated with tubulin-binding agents (TBA).
State Of Art:
High expression of class III beta-tubulin has been found to be correlated with low response rates and reduced survival in advanced NSCLC patients treated with taxane/vinorelbine--containing regimens. Two studies have shown that patients receiving paclitaxel whose tumours expressed high levels of class III beta-tubulin had a lower response rate and shorter survival, whereas this variable was not found to be predictive in patients receiving regimens without TBA. Conversely, analysis of samples from operable NSCLC patients in the JBR-10 trial showed that cisplatin/vinorelbine chemotherapy seemed to overcome the negative prognostic effect of high class III beta-tubulin expression and that the greatest benefit from chemotherapy was observed in patients with high class III beta-tubulin expression.
Perspectives:
In advanced NSCLC, high betaIII tubulin expression may prompt selection of taxane-free regimens as the preferred initial treatment approach. The epothilones may fulfil such a role in the treatment of NSCLC.
Conclusions:
betaIII tubulin expression is emerging as a valuable biomarker for taxane resistance in advanced disease, as well as offering prognostic information for outcomes among patients with earlier stage disease.
Insights
High class III beta-tubulin expression predicts poor outcomes in nonsmall cell lung cancer (NSCLC) patients treated with taxanes. Taxane-free regimens, like epothilones, may be preferred for advanced NSCLC with high beta-tubulin.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Context:
- Nonsmall cell lung cancer (NSCLC) treatment efficacy varies.
- Class III beta-tubulin expression is investigated as a predictive biomarker.
- Tubulin-binding agents (TBAs) are common NSCLC therapies.
Purpose:
- To evaluate the role of class III beta-tubulin expression in predicting treatment outcomes for NSCLC patients.
- To determine if class III beta-tubulin expression influences response to taxane-based chemotherapy.
Summary:
- High class III beta-tubulin expression is linked to reduced response and survival in advanced NSCLC patients receiving taxane/vinorelbine regimens.
- In operable NSCLC, cisplatin/vinorelbine chemotherapy may overcome the negative prognostic impact of high class III beta-tubulin.
- Class III beta-tubulin expression is a biomarker for taxane resistance and offers prognostic information in NSCLC.
Impact:
- High beta-tubulin expression may guide the selection of taxane-free regimens for advanced NSCLC.
- Epothilones are suggested as a potential taxane-free treatment option for NSCLC.
- Class III beta-tubulin serves as a valuable biomarker for taxane resistance and prognosis in NSCLC.